Crossmark

Subpopulation-specific machine learning prognosis for underrepresented patients with double prioritized bias correction

Crossref DOI link: https://doi.org/10.1038/s43856-022-00165-w

Published Online: 2022-09-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Afrose, Sharmin

Song, Wenjia

Nemeroff, Charles B.

Lu, Chang https://orcid.org/0000-0003-0181-5888
Yao, Danfeng https://orcid.org/0000-0001-8969-2792
License Information

Text and Data Mining valid from 2022-09-01

Version of Record valid from 2022-09-01
More Information

Article History

Received: 23 April 2021

Accepted: 27 July 2022

First Online: 1 September 2022

Competing interests

: C.B.N. declares consulting for the following companies: AbbVie, ANeuroTech (a division of Anima BV), Signant Health, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Sage, BioXcel Therapeutics, Silo Pharma, XW Pharma, Engrail Therapeutics, Corcept Therapeutics Pharmaceuticals Company, SK Life Science, Alfasigma, Pasithea Therapeutic Corp., EcoR1, GoodCap Pharmaceuticals, Inc., Senseye, Clexio, Ninnion Therapeutics. CBN owns stock in Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, TRUUST Neuroimaging, and Naki Health. CBN serves on the scientific advisory boards of ANeuroTech (a division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS, Heading Health, TRUUST Neuroimaging, Pasithea Therapeutic Corp., Sage. C.B.N. is on the board of directors of Gratitude America, ADAA, Xhale Smart, Inc., and Lucy Scientific Discovery, Inc. C.B.N. has patents in antipsychotic drug delivery. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below